NLS Inficure Bio

Together with CymaBay Therapeutics Inficure Bio have co-presented positive data at the American Association for the study of Liver Diseases (AASLD). Inficure and CymaBay performed a functional study in the NIF mouse model using seladelpar, a selective peroxisome proliferator (PPAR) delta agonist currently in a Phase 3 study for Primary Biliary Cholangitis (PBC). The goal […]

InfiCure Bio has recently been granted a patent in the United States for its preclinical model. At the same time a study describing the basics of the model has been accepted for publication in online journal Scientific Reports. “We are delighted and anticipate that thanks to this attention we will strengthen our position in the […]

Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases. “We will now begin testing the effects of their drug substances in our model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia […]

Inficure Bio has recently signed an agreement with a publicly listed pharmaceutical manufacturer in the US. The deal is twice as large as the previous record-breaking deal signed last spring with a company in Switzerland. “This is a fantastic opportunity for us. Deals like this demonstrate that our international credibility is increasing”, says Sofia Mayans, […]

Lena Söderström, who was previously in charge at Senzime, is the new chairman of the board of directors of the Umeå-based company Inficure Bio. Lena Söderström has worked in the life science industry for 30 years, with over half this time spent at large international pharmaceutical and medical technology companies working as a CEO of, […]